Bed Rest With a Short Cervix on Preterm Birth

NCT07577388 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6000

Last updated 2026-05-11

No results posted yet for this study

Summary

Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.

The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.

The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).

The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.

Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.

Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length \< 25 mm in singleton pregnancies and \< 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.

The primary outcome is gestational age in days (continuous).

Conditions

  • Preterm Birth
  • Cervical Insufficiency
  • Bed Rest
  • Pregnancy Complications
  • Immobilization
  • Depression, Postpartum
  • Pregnancy Outcome
  • Infant, Premature
  • Uterine Cervical Incompetence
  • Premature Birth
  • Obstetric Labor, Premature
  • Physical Activity
  • Bone Density

Interventions

BEHAVIORAL

Activity Restriction

Recommendation to restrict physical activity in pregnant women with a short cervix. This may include increased rest or bed rest according to local clinical practice.

BEHAVIORAL

No Activity Restriction

Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER
  • University of Aberdeen

    collaborator OTHER
  • Rigshospitalet, Denmark

    collaborator OTHER
  • Odense University Hospital

    collaborator OTHER
  • Aalborg University Hospital

    collaborator OTHER
  • Zealand University Hospital

    collaborator OTHER
  • Julie Glavind

    lead OTHER

Principal Investigators

  • Julie Glavind, Senior Consultant, MD, PhD · Aarhus Univeristy Hospital, Department of Obstetrics and Gynecology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2029-02-01
Completion
2029-05-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07577388 on ClinicalTrials.gov